Evidence map›Paper›PMID 42449401›Full record

ArticleJournal of nanobiotechnology2026

Dynamic cross-linked injectable hydrogel for combined oxaliplatin-resveratrol therapy in colorectal cancer peritoneal metastasis.

Haonan Huang, Haoyu Huang, Cheng Zuo, Jing Yang, Huizi Li, Fan Jiang, Ruibing Li, Lipeng Zhang, Siyu Rao, Fanrong Ai and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haonan Huang *Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Haoyu Huang *Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Cheng Zuo *Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Jing YangSchool of Pharmacy, University of Nottingham, Nottingham, UK.
Huizi LiDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Fan JiangDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Ruibing LiDepartment of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Lipeng ZhangDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Siyu RaoDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China.
Fanrong AiSchool of Advanced Manufacturing, Nanchang University, Jiangxi, China. afr3755875@126.com.
Zhen ZongDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China. ndefy16133@ncu.edu.cn.
Shengxun MaoDepartment of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China. maoshengxun@126.com.

Funding

the internal funding project of Nanchang University 2023efyBo5the Jiangxi Province Key Research and Development Plan 20232BBE50017the Science Fund for Distinguished Young Scholars of Jiangxi Province 20224ACB214005
6 · The paper itself

Abstract

Peritoneal metastasis (PM) of colorectal cancer (CRC) remains a major therapeutic challenge due to the limited efficacy of current systemic and intraperitoneal treatments. To overcome these limitations, we developed an injectable, self-healing hydrogel constructed from a dual dynamic cross-linked network formed by borate ester and Schiff base bonds between phenylboronic acid-modified carboxymethyl chitosan (CMCS-PBA) and oxidized dextran (ODEX). This hydrogel was engineered for sustained intraperitoneal co-delivery of oxaliplatin (OXA) and resveratrol-loaded mesoporous silica nanoparticles (MSNs@RES). The system exhibited excellent biocompatibility and significantly inhibited cancer cell proliferation, migration, and invasion while inducing apoptosis and immunogenic cell death (ICD) in vitro. In a murine model of CRC peritoneal metastasis, the dual-drug-loaded hydrogel markedly suppressed tumor progression, reduced ascites formation, and prolonged survival. Proteomic analysis further revealed that treatment significantly modulated key signalling pathways, including HIF-1α-mediated angiogenesis, apoptosis-related cascades, and TGF-β-driven epithelial-mesenchymal transition (EMT). Collectively, this work presents a rationally designed localized delivery platform with significant potential for the treatment of colorectal cancer peritoneal metastasis.

Indexed as

Colorectal NeoplasmsHydrogelsOxaliplatinPeritoneal NeoplasmsResveratrolAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationChitosanDrug CarriersHumansMaleMiceAntineoplastic Agentscarboxymethyl-chitosanChitosanDrug CarriersHydrogelsOxaliplatinResveratrolSilicon DioxideColorectal peritoneal metastasisInjectable hydrogelMesoporous silica nanoparticlesOxaliplatinResveratrol

Identifiers

PMID42449401
PMCPMC13625490

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.